20/20 Biolabs(AIDX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
20/20 Biolabs
AIDX.US
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups.
306.32 B
AIDX.USMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
C
Health Care SuppliesIndustry
Industry Ranking31/45
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-537.07%E
    • Profit Margin-182.82%E
    • Gross Margin29.56%C
  • Growth ScoreB
    • Revenue YoY16.71%B
    • Net Profit YoY32.65%B
    • Total Assets YoY15.43%B
    • Net Assets YoY-101.28%E
  • Cash ScoreC
    • Cash Flow Margin51.35%C
    • OCF YoY16.71%B
  • Operating ScoreC
    • Turnover0.53C
  • Debt ScoreE
    • Gearing Ratio100.46%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    20/20 Biolabs, Inc. 1Q 2026: Revenue $353.38K, EPS ($0.28) — 10-Q Summary

    TradingView·
    US
    AIDX
    -3.73%
    TradingView·
    US
    AIDX
    -3.73%

    20/20 Biolabs | 10-Q: FY2026 Q1 Revenue: USD 353.38 K

    Earnings Watch·
    US
    AIDX
    -3.73%
    Earnings Watch·
    US
    AIDX
    -3.73%

    20/20 BioLabs reveals Q1 2026 financials and recent operational advancements.

    Unusual Whales·
    US
    AIDX
    -3.73%
    Unusual Whales·
    US
    AIDX
    -3.73%

    University of South Carolina licenses PSA Velocity Algorithm exclusively to 20/20 BioLabs in a new deal.

    Unusual Whales·
    US
    AIDX
    -3.73%
    Unusual Whales·
    US
    AIDX
    -3.73%

    HEALWELL AI Announces Conference Call for First Quarter 2026 Financial Results on May 8, 2026 | HWAIF Stock News

    StockTitan·
    US
    AIDX
    -3.73%
    StockTitan·
    US
    AIDX
    -3.73%
    © 2026 Longbridge｜Disclaimer